Hedvig Hricak

Hedvig Hricak

Auto-generated profile, based on publicly available information

Hedvig Hricak

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in Radiology
Verified
Journal Article
Closed access
HHHedvig Hricak
Hedvig Hricak
PCPeter L. Choyke
Peter L. Choyke
SESteven C. Eberhardt
Steven C. Eberhardt
SLSteven A. Leibel
Steven A. Leibel
PSPeter T. Scardino
Peter T. Scardino
The major goal for prostate cancer imaging in the next decade is more accurate disease characterization through the synthesis of anatomic, functional, and molecular imaging information. No consensus exists regarding the use of imaging for evaluating primary prostate cancers. Ultrasonography is mainly used for biopsy guidance and brachytherapy seed placement. Endorectal magnetic resonance (MR) imaging is helpful for evaluating local tumor extent, and MR spectroscopic imaging can improve this evaluation while providing information about tumor aggressiveness. MR imaging with superparamagnetic nanoparticles has high sensitivity and specificity in depicting lymph node metastases, but guidelines have not yet been developed for its use, which remains restricted to the research setting. Computed tomography (CT) is reserved for the evaluation of advanced disease. The use of combined positron emission tomography/CT is limited in the assessment of primary disease but is gaining acceptance in prostate cancer treatmen...

1 April 2021 in The Lancet Oncology
Verified
Journal Article
Closed access
HHHedvig Hricak
Hedvig Hricak
MAMay Abdel-Wahab
May Abdel-Wahab
RARifat Atun
Rifat Atun
MLMiriam Mikhail Lette
Miriam Mikhail Lette
DPDiana Paez
Diana Paez
ASAndrew M Scott
Andrew M Scott

1 March 2005 in Radiology
Verified
Journal Article
Closed access
KZKristen L. Zakian
Kristen L. Zakian
KSKanishka Sircar
Kanishka Sircar
HHHedvig Hricak
Hedvig Hricak
HCHui-Ni Chen
Hui-Ni Chen
ASAmita Shukla-Dave
Amita Shukla-Dave
JKJason A. Koutcher
Jason A. Koutcher
PURPOSE: To determine whether hydrogen 1 magnetic resonance (MR) spectroscopic imaging can be used to predict aggressiveness of prostate cancer. MATERIALS AND METHODS: All patients gave informed consent according to an institutionally approved research protocol. A total of 123 patients (median age, 58 years; age range, 40–74 years) who underwent endorectal MR imaging and MR spectroscopic imaging between January 2000 and December 2002 were included. MR imaging and spectroscopy were performed by using combined pelvic phased-array and endorectal probe. Water and lipids were suppressed, and phase-encoded data were acquired with 6.2-mm resolution. Voxels in the peripheral zone were considered suspicious for cancer if (Cho + Cr)/Cit was at least two standard deviations above the normal level, where Cho represents choline-containing compounds, Cr represents creatine and phosphocreatine, and Cit represents citrate. Correlation between metabolite ratio and four Gleason score groups identified at step-section patho...

1 June 2006 in Radiology
Verified
Journal Article
Closed access
OAOguz Akin
Oguz Akin
ESEvis Sala
Evis Sala
CMChaya S. Moskowitz
Chaya S. Moskowitz
KKKentaro Kuroiwa
Kentaro Kuroiwa
NINicole M. Ishill
Nicole M. Ishill
HHHedvig Hricak
Hedvig Hricak
Purpose: To retrospectively evaluate the accuracy of endorectal magnetic resonance (MR) imaging in the detection and local staging of transition zone prostate cancers, with pathologic analysis serving as the reference standard, and to assess MR imaging features of these cancers. Materials and Methods: The institutional review board approved this HIPAA-compliant retrospective study and waived the informed consent requirement. An institutional database of 986 patients who underwent MR imaging before radical prostatectomy yielded 148 consecutive patients with at least one transition zone cancer at step-section pathologic analysis. An additional 46 patients without transition zone cancer were randomly selected as a control group. Two readers independently reviewed MR studies to identify patients with transition zone cancers and determine the location and local extent of these cancers. Imaging features that helped in the identification of transition zone cancers were recorded. Descriptive and κ statistics, as ...

1 December 2007 in Journal of Urology
Verified
Journal Article
Closed access
SEScott E. Eggener
Scott E. Eggener
PSPeter T. Scardino
Peter T. Scardino
PCPeter R. Carroll
Peter R. Carroll
MZMichael J. Zelefsky
Michael J. Zelefsky
OSOliver Sartor
Oliver Sartor
IPInternational Task Force on Prostate Cancer and the Focal Lesion Paradigm†
International Task Force on Prostate Cancer and the Focal Lesion Paradigm†
Based on contemporary epidemiological and pathological characteristics of prostate cancer we explain the rationale for and concerns about focal therapy for low risk prostate cancer, review potential methods of delivery and propose study design parameters. Articles regarding the epidemiology, diagnosis, imaging, treatment and pathology of localized prostate cancer were reviewed with a particular emphasis on technologies applicable for focal therapy, defined as targeted ablation of a limited area of the prostate expected to contain the dominant or only focus of cancer. A consensus summary was constructed by a multidisciplinary international task force of prostate cancer experts, forming the basis of the current review. In regions with a high prevalence of prostate specific antigen screening the over detection and subsequent overtreatment of prostate cancer is common. The incidence of unifocal cancers in radical prostatectomy specimens is 13% to 38%. In many others there is an index lesion with secondary foci containing pathological features similar to those found incidentally at autopsy. Because biopsy strategies and imaging techniques can provide more precise tumor localization and characterization, there is growing interest in focal therapy targeting unifocal or biologically unifocal tumors. The major arguments against focal therapy are multifocality, limited accuracy of staging, the unpredictable aggressiveness of secondary foci and the lack of established technology for focal ablation. Emerging technologies with the potential for focal therapy include high intensity focused ultrasound, cryotherapy, radio frequency ablation and photodynamic therapy. Early detection of prostate cancer has led to concerns that while many cancers now diagnosed pose too little a threat for radical therapy, many men are reluctant to accept watchful waiting or active surveillance. Several emerging technologies seem capable of focal destruction of prostate tissue with minimal morbidity. We encourage the investigation of focal therapy in select men with low risk prostate cancer in prospective clinical trials that carefully document safety, functional outcomes and cancer control.

1 August 2007 in Radiology
Verified
Journal Article
Closed access
JZJingbo Zhang
Jingbo Zhang
RLRobert A. Lefkowitz
Robert A. Lefkowitz
NINicole M. Ishill
Nicole M. Ishill
LWLiang Wang
Liang Wang
CMChaya S. Moskowitz
Chaya S. Moskowitz
HHHedvig Hricak
Hedvig Hricak
Purpose: To retrospectively determine if solid renal cortical tumors can be differentiated on computed tomographic (CT) images on the basis of their morphologic features and enhancement patterns. Materials and Methods: Institutional review board approval was obtained and the informed consent requirement was waived for this HIPAA-compliant study. Between January 2004 and September 2005, 193 consecutive patients (age range, 19–95 years; 112 men, 81 women) with renal masses underwent total or partial nephrectomy and preoperative renal CT. Two radiologists retrospectively reviewed CT studies in an independent and blinded fashion. The pattern and degree of enhancement, lesion contour, presence of neovascularity, and calcifications were evaluated. Fisher exact tests, Pearson χ2 tests, multivariate logistic regression, and Wilcoxon rank sum tests were performed. Results: Of the 198 renal tumors (median size, 3.4 cm; range, 1.1–20.0 cm) included in this study, 108 (55%) were clear cell renal cell carcinomas (RCCs...